Terms: = Prostate cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Clinical Outcome
41 results:
1. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
2. Glycyl-tRNA Synthetase (GARS) Expression Is Associated with prostate cancer Progression and Its Inhibition Decreases Migration, and Invasion In Vitro.
Khosh Kish E; Gamallat Y; Choudhry M; Ghosh S; Seyedi S; Bismar TA
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901698
[TBL] [Abstract] [Full Text] [Related]
3. The Association between Cyclin Dependent Kinase 2 Associated Protein 1 (CDK2AP1) and Molecular Subtypes of Lethal prostate cancer.
Gamallat Y; Bakker A; Khosh Kish E; Choudhry M; Walker S; Aldakheel S; Seyedi S; Huang KC; Ghosh S; Gotto G; Bismar TA
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362115
[TBL] [Abstract] [Full Text] [Related]
4. VPRBP Functions Downstream of the Androgen Receptor and OGT to Restrict p53 Activation in prostate cancer.
Poulose N; Forsythe N; Polonski A; Gregg G; Maguire S; Fuchs M; Minner S; Sauter G; McDade SS; Mills IG
Mol Cancer Res; 2022 Jul; 20(7):1047-1060. PubMed ID: 35348747
[TBL] [Abstract] [Full Text] [Related]
5. Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive prostate cancer: A Systematic Review.
Van der Eecken K; Vanwelkenhuyzen J; Deek MP; Tran PT; Warner E; Wyatt AW; Kwan EM; Verbeke S; Van Dorpe J; Fonteyne V; Lumen N; De Laere B; Ost P
Eur Urol Oncol; 2021 Dec; 4(6):914-923. PubMed ID: 34801437
[TBL] [Abstract] [Full Text] [Related]
6. A concise review on the role of BDNF-AS in human disorders.
Ghafouri-Fard S; Khoshbakht T; Taheri M; Ghanbari M
Biomed Pharmacother; 2021 Oct; 142():112051. PubMed ID: 34426254
[TBL] [Abstract] [Full Text] [Related]
7. Long non-coding RNAs correlate with genomic stability in prostate cancer: A clinical outcome and survival analysis.
Jianfeng W; Yutao W; Jianbin B
Genomics; 2021 Sep; 113(5):3141-3151. PubMed ID: 34174340
[TBL] [Abstract] [Full Text] [Related]
8. Use of Circulating Tumor DNA for the clinical Management of Metastatic Castration-Resistant prostate cancer: A Multicenter, Real-World Study.
Dong B; Fan L; Yang B; Chen W; Li Y; Wu K; Zhang F; Dong H; Cheng H; Pan J; Zhu Y; Chi C; Dong L; Sha J; Li L; Yao X; Xue W
J Natl Compr Canc Netw; 2021 May; 19(8):905-914. PubMed ID: 33990090
[TBL] [Abstract] [Full Text] [Related]
9. Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies.
Naderi A
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1267. PubMed ID: 32706923
[TBL] [Abstract] [Full Text] [Related]
10. cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28.
Müller I; Strozyk E; Schindler S; Beissert S; Oo HZ; Sauter T; Lucarelli P; Raeth S; Hausser A; Al Nakouzi N; Fazli L; Gleave ME; Liu H; Simon HU; Walczak H; Green DR; Bartek J; Daugaard M; Kulms D
Mol Cell; 2020 Mar; 77(5):970-984.e7. PubMed ID: 31982308
[TBL] [Abstract] [Full Text] [Related]
11. Genomic correlates of clinical outcome in advanced prostate cancer.
Abida W; Cyrta J; Heller G; Prandi D; Armenia J; Coleman I; Cieslik M; Benelli M; Robinson D; Van Allen EM; Sboner A; Fedrizzi T; Mosquera JM; Robinson BD; De Sarkar N; Kunju LP; Tomlins S; Wu YM; Nava Rodrigues D; Loda M; Gopalan A; Reuter VE; Pritchard CC; Mateo J; Bianchini D; Miranda S; Carreira S; Rescigno P; Filipenko J; Vinson J; Montgomery RB; Beltran H; Heath EI; Scher HI; Kantoff PW; Taplin ME; Schultz N; deBono JS; Demichelis F; Nelson PS; Rubin MA; Chinnaiyan AM; Sawyers CL
Proc Natl Acad Sci U S A; 2019 Jun; 116(23):11428-11436. PubMed ID: 31061129
[TBL] [Abstract] [Full Text] [Related]
12. TCTP Has a Crucial Role in the Different Stages of prostate cancer Malignant Progression.
Baylot V; Karaki S; Rocchi P
Results Probl Cell Differ; 2017; 64():255-261. PubMed ID: 29149413
[TBL] [Abstract] [Full Text] [Related]
13. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for prostate cancer.
Pollack A; Kwon D; Walker G; Khor LY; Horwitz EM; Buyyounouski MK; Stoyanova R
J Natl Cancer Inst; 2017 Feb; 109(2):1-8. PubMed ID: 28376214
[TBL] [Abstract] [Full Text] [Related]
14. DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.
Liu W
Asian J Androl; 2016; 18(4):533-42. PubMed ID: 26975494
[TBL] [Abstract] [Full Text] [Related]
15. Spatial genomic heterogeneity within localized, multifocal prostate cancer.
Boutros PC; Fraser M; Harding NJ; de Borja R; Trudel D; Lalonde E; Meng A; Hennings-Yeomans PH; McPherson A; Sabelnykova VY; Zia A; Fox NS; Livingstone J; Shiah YJ; Wang J; Beck TA; Have CL; Chong T; Sam M; Johns J; Timms L; Buchner N; Wong A; Watson JD; Simmons TT; P'ng C; Zafarana G; Nguyen F; Luo X; Chu KC; Prokopec SD; Sykes J; Dal Pra A; Berlin A; Brown A; Chan-Seng-Yue MA; Yousif F; Denroche RE; Chong LC; Chen GM; Jung E; Fung C; Starmans MH; Chen H; Govind SK; Hawley J; D'Costa A; Pintilie M; Waggott D; Hach F; Lambin P; Muthuswamy LB; Cooper C; Eeles R; Neal D; Tetu B; Sahinalp C; Stein LD; Fleshner N; Shah SP; Collins CC; Hudson TJ; McPherson JD; van der Kwast T; Bristow RG
Nat Genet; 2015 Jul; 47(7):736-45. PubMed ID: 26005866
[TBL] [Abstract] [Full Text] [Related]
16. Evidence that selenium binding protein 1 is a tumor suppressor in prostate cancer.
Ansong E; Ying Q; Ekoue DN; Deaton R; Hall AR; Kajdacsy-Balla A; Yang W; Gann PH; Diamond AM
PLoS One; 2015; 10(5):e0127295. PubMed ID: 25993660
[TBL] [Abstract] [Full Text] [Related]
17. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
[TBL] [Abstract] [Full Text] [Related]
18. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy.
Udayakumar T; Shareef MM; Diaz DA; Ahmed MM; Pollack A
Semin Radiat Oncol; 2010 Oct; 20(4):258-66. PubMed ID: 20832018
[TBL] [Abstract] [Full Text] [Related]
19. Global levels of histone modifications predict prognosis in different cancers.
Seligson DB; Horvath S; McBrian MA; Mah V; Yu H; Tze S; Wang Q; Chia D; Goodglick L; Kurdistani SK
Am J Pathol; 2009 May; 174(5):1619-28. PubMed ID: 19349354
[TBL] [Abstract] [Full Text] [Related]
20. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.
Kahl P; Gullotti L; Heukamp LC; Wolf S; Friedrichs N; Vorreuther R; Solleder G; Bastian PJ; Ellinger J; Metzger E; Schüle R; Buettner R
Cancer Res; 2006 Dec; 66(23):11341-7. PubMed ID: 17145880
[TBL] [Abstract] [Full Text] [Related]
[Next]
